Citadel Advisors’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.4M | Sell |
539,232
-362,764
| -40% | -$9.67M | ﹤0.01% | 2579 |
|
|
2025
Q4 | $26M | Buy |
901,996
+751,474
| +499% | +$9.81M | ﹤0.01% | 2057 |
|
|
2025
Q3 | $1.09M | Buy |
+150,522
| New | +$1.11M | ﹤0.01% | 7360 |
|
|
2025
Q2 | – | Sell |
-415,951
| Closed | -$4.39M | – | 12702 |
|
|
2025
Q1 | $3.95M | Buy |
415,951
+150,709
| +57% | +$2.09M | ﹤0.01% | 4278 |
|
|
2024
Q4 | $3.66M | Buy |
+265,242
| New | +$4.65M | ﹤0.01% | 4491 |
|
|
2024
Q3 | – | Sell |
-66,914
| Closed | -$331K | – | 14298 |
|
|
2024
Q2 | $319K | Buy |
66,914
+36,111
| +117% | +$201K | ﹤0.01% | 9013 |
|
|
2024
Q1 | $209K | Buy |
+30,803
| New | +$149K | ﹤0.01% | 10230 |
|
|
2023
Q4 | – | Sell |
-20,861
| Closed | -$67.9K | – | 14327 |
|
|
2023
Q3 | $71.3K | Sell |
20,861
-24,787
| -54% | -$139K | ﹤0.01% | 11309 |
|
|
2023
Q2 | $218K | Buy |
45,648
+30,672
| +205% | +$135K | ﹤0.01% | 9697 |
|
|
2023
Q1 | $63.2K | Sell |
14,976
-12,335
| -45% | -$53.1K | ﹤0.01% | 11858 |
|
|
2022
Q4 | $105K | Sell |
27,311
-8,927
| -25% | -$42.6K | ﹤0.01% | 11137 |
|
|
2022
Q3 | $217K | Sell |
36,238
-10,614
| -23% | -$54.3K | ﹤0.01% | 10247 |
|
|
2022
Q2 | $163K | Sell |
46,852
-11,755
| -20% | -$41.7K | ﹤0.01% | 10895 |
|
|
2022
Q1 | $201K | Sell |
58,607
-21,231
| -27% | -$83.8K | ﹤0.01% | 11527 |
|
|
2021
Q4 | $234K | Sell |
79,838
-31,712
| -28% | -$111K | ﹤0.01% | 11518 |
|
|
2021
Q3 | $448K | Buy |
111,550
+41,891
| +60% | +$191K | ﹤0.01% | 10145 |
|
|
2021
Q2 | $357K | Buy |
69,659
+23,361
| +50% | +$99K | ﹤0.01% | 10842 |
|
|
2021
Q1 | $217K | Buy |
46,298
+9,595
| +26% | +$55.3K | ﹤0.01% | 11537 |
|
|
2020
Q4 | $126K | Buy |
36,703
+1,256
| +4% | +$5.45K | ﹤0.01% | 10060 |
|
|
2020
Q3 | $186K | Buy |
35,447
+5,094
| +17% | +$29.7K | ﹤0.01% | 8866 |
|
|
2020
Q2 | $140K | Buy |
30,353
+6,474
| +27% | +$28.2K | ﹤0.01% | 8791 |
|
|
2020
Q1 | $28K | Buy |
23,879
+12,479
| +109% | +$17.4K | ﹤0.01% | 9207 |
|
|
2019
Q4 | $15K | Buy |
+11,400
| New | +$23.5K | ﹤0.01% | 8973 |
|
|
2019
Q2 | – | Sell |
-7,701
| Closed | -$36K | – | 9199 |
|
|
2019
Q1 | $36K | Buy |
7,701
+4,396
| +133% | +$22.6K | ﹤0.01% | 8941 |
|
|
2018
Q4 | $14K | Buy |
3,305
+1,658
| +101% | +$13.2K | ﹤0.01% | 8854 |
|
|
2018
Q3 | $17K | Buy |
+1,647
| New | +$19.6K | ﹤0.01% | 9036 |
|
|
2018
Q1 | – | Sell |
-1,001
| Closed | -$16K | – | 8292 |
|
|
2017
Q4 | $16K | Buy |
+1,001
| New | +$21.7K | ﹤0.01% | 7862 |
|
|
2016
Q4 | – | Sell |
-2,817
| Closed | -$93K | – | 7277 |
|
|
2016
Q3 | $93K | Buy |
+2,817
| New | +$106K | ﹤0.01% | 6680 |
|
Other funds holding CAPR
SCM
TCM
VCM
RCM
JHC
Citadel Advisors's CAPR Position: Q1 2026 in Review
Citadel Advisors reduced its Capricor Therapeutics (CAPR) stake by 40% in Q1 2026, selling an estimated $9.67M and leaving 539,232 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2579.
Citadel Advisors first reported a position in CAPR in Q3 2016 and has held it in 28 quarters since. The position peaked at $26M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.
- Citadel Advisors held 539,232 shares of Capricor Therapeutics worth $16.4M as of Q1 2026.
- Citadel Advisors sold 362,764 Capricor Therapeutics shares in Q1 2026, an estimated $9.67M.
- Capricor Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2579 holding.
- Citadel Advisors first reported a position in Capricor Therapeutics in Q3 2016 and has held it in 28 quarters since.
- Citadel Advisors's Capricor Therapeutics position peaked at $26M in Q4 2025.
- 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.